Abstract
Gastrointestinal (G-I) cancers are one of the most common malignant tumors worldwide. Symptoms relate to the organ affected in the G-I tract are non-specific, making early detection and effective treatment difficult to achieve. Epithelial-mesenchymal transition (EMT), a reversible and dynamical process, can disperse cells in embryos, form mesenchymal cells in injured tissues, and regulate embryonic stem cell differentiation. A variety of signaling molecules and distinct pathways are involved in the initiation and progression of EMT. Recent evidence has established that EMT may endow G-I cancer cells with the capacity to invade surrounding tissues, resist apoptosis, migrate to distant organs, and develop chemoresistance. Targeting these signaling molecules and pathways associated with EMT may provide clinicians with a new approach to the treatment of G-I malignancy.
Keywords: Chemoresistance, epithelial-mesenchymal transition (EMT), gastro-intestinal (G-I) cancer, metastasis, signaling, tumor progression.
Current Pharmaceutical Design
Title:Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer
Volume: 21 Issue: 21
Author(s): Hueng-Chuen Fan, Shinn-Zong Lin and Horng-Jyh Harn
Affiliation:
Keywords: Chemoresistance, epithelial-mesenchymal transition (EMT), gastro-intestinal (G-I) cancer, metastasis, signaling, tumor progression.
Abstract: Gastrointestinal (G-I) cancers are one of the most common malignant tumors worldwide. Symptoms relate to the organ affected in the G-I tract are non-specific, making early detection and effective treatment difficult to achieve. Epithelial-mesenchymal transition (EMT), a reversible and dynamical process, can disperse cells in embryos, form mesenchymal cells in injured tissues, and regulate embryonic stem cell differentiation. A variety of signaling molecules and distinct pathways are involved in the initiation and progression of EMT. Recent evidence has established that EMT may endow G-I cancer cells with the capacity to invade surrounding tissues, resist apoptosis, migrate to distant organs, and develop chemoresistance. Targeting these signaling molecules and pathways associated with EMT may provide clinicians with a new approach to the treatment of G-I malignancy.
Export Options
About this article
Cite this article as:
Fan Hueng-Chuen, Lin Shinn-Zong and Harn Horng-Jyh, Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514103513
DOI https://dx.doi.org/10.2174/1381612821666150514103513 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Meet Our Editorial Board Member
Current Medicinal Chemistry RNAi in Clinical Studies
Current Medicinal Chemistry The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry Drug Acyl Glucuronides: Reactivity and Analytical Implication
Current Pharmaceutical Analysis The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews Reflux Extraction and Column Chromatography for Rosmarinic Acid- Rich Fraction from Orthosiphon stamineus
The Natural Products Journal Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Hydatid Disease: Current Status of Chemotherapy and Drug Delivery Systems
Current Drug Therapy Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Sentinel Node Imaging
Current Medical Imaging Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry